Methods for Evaluation of Antivirals and Neutralizing Antibodies Against Tick-Borne Encephalitis Virus
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
- Klíčová slova
- Antivirals, Immunofluorescence, Monoclonal antibodies, Mouse infection, Neutralization test, Plaque assay, Tick-borne encephalitis virus,
- MeSH
- antivirové látky * farmakologie MeSH
- buněčné linie MeSH
- klíšťová encefalitida * virologie farmakoterapie imunologie MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- monoklonální protilátky imunologie MeSH
- myši MeSH
- neutralizační testy metody MeSH
- neutralizující protilátky * imunologie farmakologie MeSH
- plakové testy MeSH
- protilátky virové * imunologie MeSH
- viry klíšťové encefalitidy * účinky léků imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antivirové látky * MeSH
- monoklonální protilátky MeSH
- neutralizující protilátky * MeSH
- protilátky virové * MeSH
Tick-borne encephalitis (TBE) is a potentially fatal neuroinfection of humans caused by the TBE virus. There is no specific therapy for TBE, as treatment is only supportive. Therefore, efforts to develop an effective specific therapy for TBE are warranted. Small molecule inhibitors and monoclonal antibodies are under intense investigation as potential therapeutics to combat TBE in humans. Here we describe the basic methods that can be used to test small molecule antivirals or monoclonal antibodies against TBEV. These include in vitro methods such as plaque assays, neutralizing assays, immunofluorescence staining of viral antigen, and cell-based antiviral assays, as well as in vivo assays in mouse model of TBE.
Faculty of Science Masaryk University Brno Czech Republic
Faculty of Veterinary Medicine University of Veterinary Sciences Brno Czech Republic
Zobrazit více v PubMed
Ruzek D et al (2019) Tick-borne encephalitis in Europe and Russia: review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res 164:23–51 PubMed DOI
Holding M et al (2019) Detection of new endemic focus of tick-borne encephalitis virus (TBEV), Hampshire/Dorset border, England. Euro Surveill 24(47):24 DOI
Holding M et al (2020) Tick-borne encephalitis virus, United Kingdom. Emerg Infect Dis 26(1):90–96 PubMed DOI PMC
Fares W et al (2021) Tick-borne encephalitis virus in Ixodes ricinus (Acari: Ixodidae) ticks, Tunisia. Ticks Tick Borne Dis 12(1):101606 PubMed DOI
Bogovic P, Strle F (2015) Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management. World J Clin Cases 3(5):430–441 PubMed DOI PMC
Kohlmaier B et al (2021) Clinical characteristics of patients with tick-borne encephalitis (TBE): a European multicentre study from 2010 to 2017. Microorganisms 9(7):1420 PubMed DOI PMC
Eyer L, Seley-Radtke K, Ruzek D (2023) New directions in the experimental therapy of tick-borne encephalitis. Antiviral Res 210:105504 PubMed DOI
Eyer L et al (2017) Escape of tick-borne Flavivirus from 2'-C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness. J Virol 91(21):e01028 PubMed DOI PMC
Eyer L et al (2019) An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice. J Virol 93(16):e00367 PubMed DOI PMC
Eyer L et al (2016) Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antiviral Res 133:119–129 PubMed DOI
Eyer L et al (2015) Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob Agents Chemother 59(9):5483–5493 PubMed DOI PMC
Osolodkin DI et al (2013) Inhibitors of tick-borne flavivirus reproduction from structure-based virtual screening. ACS Med Chem Lett 4(9):869–874 PubMed DOI PMC
Ruzek D (2022) Animal models of tick-borne encephalitis for preclinical antiviral research. In: Annual reports in medicinal chemistry, pp 243–256
Agudelo M et al (2021) Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J Exp Med 218(5):e20210236 PubMed DOI PMC
Baykov IK et al (2014) A protective chimeric antibody to tick-borne encephalitis virus. Vaccine 32(29):3589–3594 PubMed DOI
Levanov LN et al (2010) Chimeric antibodies against tick-borne encephalitis virus. Vaccine 28(32):5265–5271 PubMed DOI
Matveev AL et al (2019) Post-exposure administration of chimeric antibody protects mice against European, Siberian, and Far-Eastern subtypes of tick-borne encephalitis virus. PLoS One 14(4):e0215075 PubMed DOI PMC
Eyer L et al (2021) Broad-Spectrum antiviral activity of 3'-Deoxy-3'-Fluoroadenosine against emerging Flaviviruses. Antimicrob Agents Chemother 65(2):e01522 PubMed DOI PMC
